PDL BioPharma to Present at the 4th Annual Credit Suisse Small/Mid Cap Conference
INCLINE VILLAGE, Nev., Sept. 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 4th Annual Credit Suisse Small/Mid Cap Conference in New York City on Tuesday, September 17, 2013. Presentations at this conference will not be available via webcast.
(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new income generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
RELATED LINKS
http://www.pdl.com
More by this Source
PDL BioPharma Provides $60 Million in Financing to LENSAR
Oct 02, 2013, 07:00 ET
PDL BioPharma Completes Regular Quarterly Dividend Payment
Sep 12, 2013, 07:00 ET
PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million
Sep 09, 2013, 07:00 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.
- Site Preview
-
Close Site Preview
-
View FullScreen
